Sientra's Stock Soars: FDA Approves Its Portfinder Tech For Improved Usage In Plastic Surgery Procedures

The FDA granted a 510(k) clearance to Sientra Inc's SIEN Portfinder technology, an electronic handheld device that allows for the subcutaneous location of ports in Sientra's Dermaspan and AlloX2 Pro tissue expanders. 

This new technology replaces the traditional dangle magnet mechanism and provides clinicians with a more accurate port location with improved useability.

Portfinder's technology improves the user experience during tissue expander filling sessions, allowing for more precision and confidence in the port location. 

The Portfinder's interactive screen guides the user towards the center of the ports and allows for precise identification and marking of both fill and drain ports in Dermaspan and AlloX2 Pro expanders, making it a very versatile device", said Dr. Denise Dajles, Sientra's Chief Technical Officer.

In Q1 FY23, Sientra reported net sales of $22.6 million, representing growth of 5.4% over the first quarter of 2022, driven by strong growth in reconstruction.

Price Action: SIEN shares are up 19.1% at $1.93 on the last check Wednesday.